(NASDAQ: CNTX) Context Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.18%.
Context Therapeutics's earnings in 2026 is -$45,957,842.On average, 11 Wall Street analysts forecast CNTX's earnings for 2026 to be -$43,109,710, with the lowest CNTX earnings forecast at -$51,323,708, and the highest CNTX earnings forecast at -$38,589,254. On average, 10 Wall Street analysts forecast CNTX's earnings for 2027 to be -$40,702,475, with the lowest CNTX earnings forecast at -$53,124,540, and the highest CNTX earnings forecast at -$35,695,060.
In 2028, CNTX is forecast to generate -$50,965,379 in earnings, with the lowest earnings forecast at -$63,029,115 and the highest earnings forecast at -$38,304,429.